News about "Viatris "

Viatris Secures Japan Approval for Effexor SR as First Treatment for Generalised Anxiety Disorder

Japan’s health ministry approves Effexor SR for adult GAD, marking the first and only authorised treatment in the country and expanding access to mental health care.

Viatris | 24/03/2026 | By News Bureau

Viatris Inc sNDA for MR-141 Accepted by U.S. Food and Drug Administration for Presbyopia Treatment

The US FDA has accepted Viatris’ supplemental application for phentolamine ophthalmic solution 0.75 percent to treat presbyopia and advancing to a potential non-invasive therapy.

Viatris | 02/03/2026 | By News Bureau

Biocon Raises INR 4,150 Crore via QIP

Biocon has successfully raised INR 4,150 crore through a Qualified Institutions Placement (QIP), with the proceeds set to be primarily used to fund the cash consideration payable to Mylan Inc. (Viatris) for the buyout of its stake in Biocon Biologics, including the repayment of related acquisition debt.

Viatris | 15/01/2026 | By News Bureau |  113

Biocon Biologics Secures Global Rights to Hulio

The new agreement supersedes the existing collaboration agreement between Biocon Biologics and Fujifilm Kyowa Kirin Biologics (FKB) for biosimilar Adalimumab, under which Biocon Biologics only had commercialisation rights.

Viatris | 23/12/2025 | By News Bureau |  136

Viatris to Receive USD 400 Million in Cash and USD 415 Million in Equity Shares of Biocon

Viatris is set to receive USD 400 million in cash and USD 415 million in Biocon equity shares as part of a revised agreement, accelerating the end of non-compete restrictions in the biosimilars space and enabling both companies to pursue expanded market opportunities.

Viatris | 08/12/2025 | By Dineshwori

Viatris Acquires Aculys Pharma, Secures Exclusive Rights to Pitolisant and Spydia in Japan

Viatris has completed the acquisition of Aculys Pharma, a clinical stage biopharmaceutical company focused on commercialising innovative treatments for neurological conditions.

Viatris | 16/10/2025 | By Dineshwori |  583

Viatris Names Andrew Enrietti Chief Administrative and Transformation Officer

Viatris Inc. has appointed Andrew Enrietti as its Chief Administrative and Transformation Officer – a newly created position.

Viatris | 20/08/2025 | By Dineshwori |  216

MPP-ViiV Agreement Expanded: Aurobindo, Cipla and Viatris to Make Generic HIV Drug Cabotegravir

ViiV Healthcare and the Medicines Patent Pool (MPP) have expanded their voluntary licensing agreement for cabotegravir, enabling manufacturers such as Aurobindo, Cipla, and Viatris to develop, manufacture, and supply generic versions for the HIV treatment in 133 countries.

Viatris | 15/07/2025 | By Dineshwori |  428

Nxera Pharma Assigns Japan Rights to Cenerimod for Autoimmune Diseases to Viatris

Nxera will receive an upfront payment of USD 10 million from Viatris and is eligible to receive a milestone payment upon regulatory approval of cenerimod in Japan plus royalties on net sales should it be commercialized in the assigned territories.

Viatris | 28/02/2025 | By Aishwarya |  519

Viatris Signs Licensing Deal with Lexicon Pharmaceuticals for Sotagliflozin

This licensing agreement leverages Viatris' expertise in cardiovascular diseases and its Global Healthcare Gateway, which offers partners ready access to more markets and patients worldwide through the company's unique global infrastructure and expertise.

Viatris | 18/10/2024 | By Aishwarya |  643